Renal cell carcinoma (RCC) subtypes are increasingly being discerned via their molecular underpinnings. Frequently this can be correlated to histologic and immunohistochemical surrogates, such that only simple targeted molecular assays, or none at all, are needed for diagnostic confirmation. In clear cell RCC, VHL mutation and 3p loss are well known; however, other genes with emerging important roles include SETD2, BAP1, and PBRM1, among others. Papillary RCC type 2 is now known to include likely several different molecular entities, such as fumarate hydratase (FH) deficient RCC. In MIT family translocation RCC, an increasing number of gene fusions are now described. Some TFE3 fusion partners, such as NONO, GRIPAP1, RBMX, and RBM10 may show a deceptive fluorescence in situ hybridization result due to the proximity of the genes on the same chromosome. FH and succinate dehydrogenase deficient RCC have implications for patient counseling due to heritable syndromes and the aggressiveness of FH-deficient RCC. Immunohistochemistry is increasingly available and helpful for recognizing both. Emerging tumor types with strong evidence for distinct diagnostic entities include eosinophilic solid and cystic RCC and TFEB/VEGFA/6p21 amplified RCC. Other emerging entities that are less clearly understood include TCEB1 mutated RCC, RCC with ALK rearrangement, renal neoplasms with mutations of TSC2 or MTOR, and RCC with fibromuscular stroma. In metastatic RCC, the role of molecular studies is not entirely defined at present, although there may be an increasing role for genomic analysis related to specific therapy pathways, such as for tyrosine kinase or MTOR inhibitors.

Cancer Diagnosis and Pathology Research Group Kolling Institute of Medical Research Royal North Shore Hospital St Leonards

Department of Oncology and Pathology Karolinska Institutet Stockholm Sweden

Department of Pathology and Laboratory Medicine and Henry Ford Cancer Institute Henry Ford Health System

Department of Pathology Charles University Medical Faculty and Charles University Hospital Plzen Pilsen Czechia

Department of Pathology Indiana University School of Medicine Indianapolis IN

Department of Pathology Johns Hopkins University School of Medicine Baltimore MD

Department of Pathology Memorial Sloan Kettering Cancer Center New York NY

Department of Pathology Wayne State University School of Medicine Detroit MI

Institute of Pathology University Hospital Bonn Bonn Germany

NSW Health Pathology Department of Anatomical Pathology

Sydney Medical School University of Sydney Sydney NSW Australia

Zobrazit více v PubMed

Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105. PubMed

Brugarolas J Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol. 2014;32:1968–1976. PubMed PMC

Carlo MI, Hakimi AA, Stewart GD, et al. Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. Eur Urol. 2019. PubMed PMC

Motzer RJ, Jonasch E, Agarwal N, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Kidney Cancer. 2019. Available at: https://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf. Accessed 8/28/2019.

Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol. 2013;37:1469–1489. PubMed

Moch H, Bonsib SM, Delahunt B, et al. Clear cell renal cell carcinoma In: Moch H, Humphrey PA, Ulbright TM., et al. eds. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: International Agency for Research on Cancer; 2016:18–21.

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–49. PubMed PMC

Sato Y, Yoshizato T, Shiraishi Y, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013;45:860–867. PubMed

Chen F, Zhang Y, Senbabaoglu Y, et al. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep. 2016;14:2476–2489. PubMed PMC

Magers MJ, Cheng L. Practical Molecular Testing in a Clinical Genitourinary Service. Arch Pathol Lab Med. 2019. PubMed

Williamson SR, Grignon DJ, Cheng L, et al. Renal cell carcinoma with chromosome 6p amplification including the TFEB gene: a novel mechanism of tumor pathogenesis? Am J Surg Pathol. 2017;41:287–298. PubMed

Klatte T, Said JW, Seligson DB, et al. Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. J Urol. 2011;185:30–35. PubMed

Chen YB, Xu J, Skanderup AJ, et al. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat Commun. 2016;7:13131. PubMed PMC

Favazza L, Chitale DA, Barod R, et al. Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database. Mod Pathol. 2017;30:1603–1612. PubMed

Piva F, Santoni M, Matrana MR, et al. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Rev Mol Diagn. 2015;15:1201–1210. PubMed

Al-Ahmadie HA, Alden D, Fine SW, et al. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol. 2011;35:949–961. PubMed

Al-Ahmadie HA, Alden D, Qin LX, et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol. 2008;32:377–382. PubMed

Donato DP, Johnson MT, Yang XJ, et al. Expression of carbonic anhydrase IX in genitourinary and adrenal tumours. Histopathology. 2011;59:1229–1239. PubMed

Genega EM, Ghebremichael M, Najarian R, et al. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol. 2010;134:873–879. PubMed PMC

Stillebroer AB, Mulders PF, Boerman OC, et al. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010;58:75–83. PubMed

Feldman DR, Iyer G, Van Alstine L, et al. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. Clin Cancer Res. 2014;20:3712–3720. PubMed

Rohan SM, Xiao Y, Liang Y, et al. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol. 2011;24:1207–1220. PubMed

Delahunt B, Algaba F, Eble J, et al. Papillary renal cell carcinoma In: Moch H, Humphrey PA, Ulbright TM., et al. eds. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: International Agency for Research on Cancer; 2016:23–25.

Pitra T, Pivovarcikova K, Alaghehbandan R, et al. Chromosomal numerical aberration pattern in papillary renal cell carcinoma: Review article. Ann Diagn Pathol. 2019;40:189–199. PubMed

Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016;374:135–145. PubMed PMC

Saleeb RM, Brimo F, Farag M, et al. Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis. Am J Surg Pathol. 2017;41:1618–1629. PubMed

Lee BH. Commentary on: “Comprehensive molecular characterization of papillary renal-cell carcinoma.” Cancer Genome Atlas Research Network.: N Engl J Med. 2016. January 14;374(2):135–45. Urol Oncol. 2017;35:578–579. PubMed PMC

Zbar B, Tory K, Merino M, et al. Hereditary papillary renal cell carcinoma. J Urol. 1994;151:561–566. PubMed

Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68–73. PubMed

Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Curr Mol Med. 2004;4:855–868. PubMed

Akhtar M, Al-Bozom IA, Al Hussain T. Papillary Renal Cell Carcinoma (PRCC): An Update. Adv Anat Pathol. 2019;26:124–132. PubMed

Lubensky IA, Schmidt L, Zhuang Z, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol. 1999;155:517–526. PubMed PMC

Rhoades Smith KE, Bilen MA. A Review of Papillary Renal Cell Carcinoma and MET Inhibitors. Kidney Cancer. 2019;3:151–161. PubMed PMC

Schoffski P, Wozniak A, Escudier B, et al. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. Eur J Cancer. 2017;87:147–163. PubMed

Gilbert JA. Savolitinib for MET-driven papillary renal cell carcinoma. Lancet Oncol. 2017;18:e440. PubMed

Fay AP, Signoretti S, Choueiri TK. MET as a target in papillary renal cell carcinoma. Clin Cancer Res. 2014;20:3361–3363. PubMed

Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31:181–186. PubMed PMC

Lefevre M, Couturier J, Sibony M, et al. Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases. Am J Surg Pathol. 2005;29:1576–1581. PubMed

Han G, Yu W, Chu J, et al. Oncocytic papillary renal cell carcinoma: A clinicopathological and genetic analysis and indolent clinical course in 14 cases. Pathol Res Pract. 2017;213:1–6. PubMed

Kunju LP, Wojno K, Wolf JS Jr., et al. Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol. 2008;39:96–101. PubMed

Hes O, Brunelli M, Michal M, et al. Oncocytic papillary renal cell carcinoma: a clinicopathologic, immunohistochemical, ultrastructural, and interphase cytogenetic study of 12 cases. Ann Diagn Pathol. 2006;10:133–139. PubMed

Al-Obaidy KI, Eble JN, Nassiri M, et al. Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. Mod Pathol. 2019:epub ahead of print. PubMed

Al-Obaidy KI, Eble JN, Cheng L, et al. Papillary Renal Neoplasm With Reverse Polarity: A Morphologic, Immunohistochemical, and Molecular Study. Am J Surg Pathol 2019;43:1099–1111. PubMed

Tong K, Zhu W, Fu H, et al. Frequent KRAS Mutations in Oncocytic Papillary Renal Neoplasm with Inverted Nuclei. Histopathology. 2020. PubMed

Williamson SR, Gadde R, Trpkov K, et al. Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. Hum Pathol. 2017;63:149–156. PubMed

Delongchamps NB, Galmiche L, Eiss D, et al. Hybrid tumour ‘oncocytoma-chromophobe renal cell carcinoma’ of the kidney: a report of seven sporadic cases. BJU Int. 2009;103:1381–1384. PubMed

Petersson F, Gatalica Z, Grossmann P, et al. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch. 2010;456:355–365. PubMed

Tickoo SK, Reuter VE, Amin MB, et al. Renal oncocytosis: a morphologic study of fourteen cases. Am J Surg Pathol. 1999;23:1094–1101. PubMed

Gobbo S, Eble JN, Delahunt B, et al. Renal cell neoplasms of oncocytosis have distinct morphologic, immunohistochemical, and cytogenetic profiles. Am J Surg Pathol. 2010;34:620–626. PubMed

Speicher MR, Schoell B, du Manoir S, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994;145:356–364. PubMed PMC

Paner G, Amin MB, Moch H, et al. Chromophobe renal cell carcinoma In: Moch H, Humphrey PA, Ulbright TM., et al. eds. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: International Agency for Research on Cancer; 2016:27–28.

Davis CF, Ricketts CJ, Wang M, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014;26:319–330. PubMed PMC

Vieira J, Henrique R, Ribeiro FR, et al. Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. Genes Chromosomes Cancer. 2010;49:935–947. PubMed

Sperga M, Martinek P, Vanecek T, et al. Chromophobe renal cell carcinoma--chromosomal aberration variability and its relation to Paner grading system: an array CGH and FISH analysis of 37 cases. Virchows Arch. 2013;463:563–573. PubMed

Tan MH, Wong CF, Tan HL, et al. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer. 2010;10:196. PubMed PMC

Joshi S, Tolkunov D, Aviv H, et al. The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. Cell Rep. 2015;13:1895–1908. PubMed PMC

Xiao GQ, Ko HB, Unger P. Telangiectatic oncocytoma: a previously undescribed variant of renal oncocytoma. Am J Clin Pathol. 2013;140:103–108. PubMed

Skenderi F, Ulamec M, Vranic S, et al. Cystic Renal Oncocytoma and Tubulocystic Renal Cell Carcinoma: Morphologic and Immunohistochemical Comparative Study. Appl Immunohistochem Mol Morphol. 2016;24:112–119. PubMed

Hes O, Michal M, Boudova L, et al. Small cell variant of renal oncocytoma--a rare and misleading type of benign renal tumor. Int J Surg Pathol. 2001;9:215–222. PubMed

Kuroda N, Yorita K, Naroda T, et al. Renal oncocytoma, small cell variant, with pseudorosettes, showing cyclin D1 expression and tubulovesicular cristae of mitochondria. Pathol Int. 2016;66:409–410. PubMed

Magro G, Gardiman MP, Lopes MR, et al. Small-cell variant of renal oncocytoma with dominating solid growth pattern: a potential diagnostic pitfall. Virchows Arch. 2006;448:379–380. PubMed

Petersson F, Sima R, Grossmann P, et al. Renal small cell oncocytoma with pseudorosettes A histomorphologic, immunohistochemical, and molecular genetic study of 10 cases. Hum Pathol. 2011;42:1751–1760. PubMed

Zhang W, Yu W, Wang Q, et al. The clinicopathological, ultrastructural, genetic features and diagnosis of small cell variant renal oncocytoma. Acta Histochem. 2015;117:505–511. PubMed

Wobker SE, Williamson SR. Modern Pathologic Diagnosis of Renal Oncocytoma. J Kidney Cancer VHL. 2017;4:1–12. PubMed PMC

Hes O, Moch H, Reuter V. Oncocytoma In: Moch H, Humphrey PA, Ulbright TM., et al. eds. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: International Agency for Research on Cancer; 2016:43–44.

Hes O, Michal M, Kuroda N, et al. Vimentin reactivity in renal oncocytoma: immunohistochemical study of 234 cases. Arch Pathol Lab Med. 2007;131:1782–1788. PubMed

Crotty TB, Lawrence KM, Moertel CA, et al. Cytogenetic analysis of six renal oncocytomas and a chromophobe cell renal carcinoma. Evidence that -Y, −1 may be a characteristic anomaly in renal oncocytomas. Cancer Genet Cytogenet. 1992;61:61–66. PubMed

Fuzesi L, Gunawan B, Braun S, et al. Renal oncocytoma with a translocation t(9;11)(p23;q13). J Urol. 1994;152:471–472. PubMed

Paner GP, Lindgren V, Jacobson K, et al. High incidence of chromosome 1 abnormalities in a series of 27 renal oncocytomas: cytogenetic and fluorescence in situ hybridization studies. Arch Pathol Lab Med. 2007;131:81–85. PubMed

Lindgren V, Paner GP, Omeroglu A, et al. Cytogenetic analysis of a series of 13 renal oncocytomas. J Urol. 2004;171:602–604. PubMed

Picken MM, Chyna B, Flanigan RC, et al. Analysis of chromosome 1p abnormalities in renal oncocytomas by loss of heterozygosity studies: correlation with conventional cytogenetics and fluorescence in situ hybridization. Am J Clin Pathol. 2008;129:377–382. PubMed

Anderson CB, Lipsky M, Nandula SV, et al. Cytogenetic analysis of 130 renal oncocytomas identify three distinct and mutually exclusive diagnostic classes of chromosome aberrations. Genes Chromosomes Cancer. 2019. PubMed

Sukov WR, Ketterling RP, Lager DJ, et al. CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma. Hum Pathol. 2009;40:1296–1303. PubMed

Tickoo SK, dePeralta-Venturina MN, Harik LR, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol. 2006;30:141–153. PubMed

Adam J, Couturier J, Molinie V, et al. Clear-cell papillary renal cell carcinoma: 24 cases of a distinct low-grade renal tumour and a comparative genomic hybridization array study of seven cases. Histopathology. 2011;58:1064–1071. PubMed

Aron M, Chang E, Herrera L, et al. Clear cell-papillary renal cell carcinoma of the kidney not associated with end-stage renal disease: clinicopathologic correlation with expanded immunophenotypic and molecular characterization of a large cohort with emphasis on relationship with renal angiomyoadenomatous tumor. Am J Surg Pathol. 2015;39:873–888. PubMed

Aydin H, Chen L, Cheng L, et al. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol. 2010;34:1608–1621. PubMed

Deml KF, Schildhaus HU, Comperat E, et al. Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma. Am J Surg Pathol. 2015;39:889–901. PubMed PMC

Diolombi ML, Cheng L, Argani P, et al. Do clear cell papillary renal cell carcinomas have malignant potential? Am J Surg Pathol. 2015;39:1621–1634. PubMed

Leroy X, Camparo P, Gnemmi V, et al. Clear cell papillary renal cell carcinoma is an indolent and low-grade neoplasm with overexpression of cyclin-D1. Histopathology. 2014;64:1032–1036. PubMed

Srigley JR, Cheng L, Grignon DJ, et al. Clear cell papillary renal cell carcinoma In: Moch H, Humphrey PA, Ulbright TM., et al. eds. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: International Agency for Research on Cancer; 2016:40–41.

Williamson SR, Eble JN, Cheng L, et al. Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile. Mod Pathol. 2013;26:697–708. PubMed

Zhou H, Zheng S, Truong LD, et al. Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma. Hum Pathol. 2014;45:59–64. PubMed

Mantilla JG, Antic T, tretiakova MS. GATA-3 Is a Specific Marker for Clear Cell Papillary Renal Cell Carcinoma. Mod Pathol. 2017;30:241A (abstract). PubMed

Martignoni G, Brunelli M, Segala D, et al. Validation of 34betaE12 immunoexpression in clear cell papillary renal cell carcinoma as a sensitive biomarker. Pathology. 2017;49:10–18. PubMed

Morlote D, Rais-Bahrami S, Harada S, et al. A Molecular Profile of Clear Cell Papillary Renal Cell Carcinoma by Next Generation Sequencing. Mod Pathol. 2018;31:370 (abstract).

Xu J, Reznik E, Lee HJ, et al. Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. Elife. 2019;8. PubMed PMC

Fisher KE, Yin-Goen Q, Alexis D, et al. Gene expression profiling of clear cell papillary renal cell carcinoma: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Mod Pathol. 2014;27:222–230. PubMed

Inoue T, Matsuura K, Yoshimoto T, et al. Genomic profiling of renal cell carcinoma in patients with end-stage renal disease. Cancer Sci. 2012;103:569–576. PubMed PMC

Munari E, Marchionni L, Chitre A, et al. Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Hum Pathol. 2014;45:1130–1138. PubMed PMC

Wolfe A, Dobin SM, Grossmann P, et al. Clonal trisomies 7,10 and 12, normal 3p and absence of VHL gene mutation in a clear cell tubulopapillary carcinoma of the kidney. Virchows Arch. 2011;459:457–463. PubMed

Williamson SR, Cheng L. Clear cell renal cell tumors: not all that is “clear” is cancer. Urol Oncol. 2016;34:292 e217–222. PubMed

Gupta S, Inwards CY, Van Dyke DL, et al. Defining Clear Cell Papillary Renal Cell Carcinoma in Routine Clinical Practice. Histopathology. 2020. PubMed

Williamson SR, Gupta NS, Eble JN, et al. Clear cell renal cell carcinoma with borderline features of clear cell papillary renal cell carcinoma: combined morphologic, immunohistochemical, and cytogenetic analysis. Am J Surg Pathol. 2015;39:1502–1510. PubMed

Dhakal HP, McKenney JK, Khor LY, et al. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution. Am J Surg Pathol. 2016;40:141–154. PubMed

Williamson SR, Zhang S, Eble JN, et al. Clear cell papillary renal cell carcinoma-like tumors in patients with von Hippel-Lindau disease are unrelated to sporadic clear cell papillary renal cell carcinoma. Am J Surg Pathol. 2013;37:1131–1139. PubMed

Argani P MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32:103–113. PubMed

Gandhi JS, Malik F, Amin MB, et al. MiT family translocation renal cell carcinomas: A 15th anniversary update. Histol Histopathol. 2019:18159. PubMed

Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001;159:179–192. PubMed PMC

Argani P, Lui MY, Couturier J, et al. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene. 2003;22:5374–5378. PubMed

Argani P, Ladanyi M. Renal carcinomas associated with Xp11.2 translocations / TFE3 gene fusions In: Eble JN, Sauter G, Epstein JI, et al. eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004:37–38.

Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31:1149–1160. PubMed

Argani P, Hicks J, De Marzo AM, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol. 2010;34:1295–1303. PubMed PMC

Ellis CL, Eble JN, Subhawong AP, et al. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Mod Pathol. 2014;27:875–886. PubMed

Argani P, Zhong M, Reuter VE, et al. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. Am J Surg Pathol. 2016;40:723–737. PubMed PMC

Malouf GG, Su X, Yao H, et al. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20:4129–4140. PubMed PMC

Argani P, Hawkins A, Griffin CA, et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol. 2001;158:2089–2096. PubMed PMC

Gupta S, Argani P, Jungbluth AA, et al. TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations. Am J Surg Pathol. 2019;43:1445–1461. PubMed PMC

Gupta S, Johnson SH, Vasmatzis G, et al. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management. Mod Pathol. 2017;30:998–1012. PubMed

Skala SL, Xiao H, Udager AM, et al. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. Mod Pathol. 2018;31:179–197. PubMed

Peckova K, Vanecek T, Martinek P, et al. Aggressive and nonaggressive translocation t(6;11) renal cell carcinoma: comparative study of 6 cases and review of the literature. Ann Diagn Pathol. 2014;18:351–357. PubMed

Durinck S, Stawiski EW, Pavia-Jimenez A, et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet. 2015;47:13–21. PubMed PMC

Xia QY, Wang XT, Ye SB, et al. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH. Histopathology. 2018;72:786–794. PubMed

Camparo P, Vasiliu V, Molinie V, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008;32:656–670. PubMed

Martignoni G, Gobbo S, Camparo P, et al. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol. 2011;24:1313–1319. PubMed

Martignoni G, Pea M, Gobbo S, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol. 2009;22:1016–1022. PubMed

Argani P, Yonescu R, Morsberger L, et al. Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol. 2012;36:1516–1526. PubMed PMC

Green WM, Yonescu R, Morsberger L, et al. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol. 2013;37:1150–1163. PubMed

Rao Q, Williamson SR, Zhang S, et al. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol. 2013;37:804–815. PubMed

Xia QY, Wang Z, Chen N, et al. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement. Mod Pathol. 2017;30:416–426. PubMed

Argani P, Zhang L, Reuter VE, et al. RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH. Am J Surg Pathol. 2017;41:655–662. PubMed PMC

Just PA, Letourneur F, Pouliquen C, et al. Identification by FFPE RNA-Seq of a new recurrent inversion leading to RBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern. Genes Chromosomes Cancer. 2016;55:541–548. PubMed

Xia QY, Wang XT, Zhan XM, et al. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3. Am J Surg Pathol. 2017;41:663–676. PubMed

Classe M, Malouf GG, Su X, et al. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas. Histopathology. 2017;70:1089–1097. PubMed

Argani P, Zhang L, Sung YS, et al. A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor. Genes Chromosomes Cancer. 2019. PubMed PMC

Ohe C, Smith SC, Sirohi D, et al. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma. Am J Surg Pathol. 2018;42:279–292. PubMed PMC

Jia L, Carlo MI, Khan H, et al. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases. Mod Pathol. 2019;32:1329–1343. PubMed PMC

Calderaro J, Masliah-Planchon J, Richer W, et al. Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas. Eur Urol. 2016;69:1055–1061. PubMed

Carlo MI, Chaim J, Patil S, et al. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. Clin Genitourin Cancer. 2017;15:e987–e994. PubMed PMC

Calderaro J, Moroch J, Pierron G, et al. SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology. 2012;61:428–435. PubMed

Liu Q, Galli S, Srinivasan R, et al. Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation. Am J Surg Pathol. 2013;37:368–374. PubMed PMC

Cheng JX, Tretiakova M, Gong C, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol. 2008;21:647–652. PubMed

Rao P, Tannir NM, Tamboli P. Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall. Am J Surg Pathol. 2012;36:583–588. PubMed

Sirohi D, Smith SC, Ohe C, et al. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma. Hum Pathol. 2017;67:134–145. PubMed

Amin MB, Smith SC, Agaimy A, et al. Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. Am J Surg Pathol. 2014;38:871–874. PubMed

Pal SK, Choueiri TK, Wang K, et al. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. Eur Urol. 2015. PubMed

Eble JN. Mucinous tubular and spindle cell carcinoma and post-neuroblastoma carcinoma: newly recognised entities in the renal cell carcinoma family. Pathology. 2003;35:499–504. PubMed

Paner GP, Srigley JR, Radhakrishnan A, et al. Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution. Am J Surg Pathol. 2006;30:13–19. PubMed

Amin MB, MacLennan GT, Gupta R, et al. Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol. 2009;33:384–392. PubMed

Zhou M, Yang XJ, Lopez JI, et al. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification. Am J Surg Pathol. 2009;33:1840–1849. PubMed

Tran T, Jones CL, Williamson SR, et al. Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma. Histopathology. 2016;68:850–857. PubMed

Kuroda N, Ohe C, Mikami S, et al. Review of acquired cystic disease-associated renal cell carcinoma with focus on pathobiological aspects. Histol Histopathol. 2011;26:1215–1218. PubMed

Tickoo SK, Kuroda N. Acquired cystic disease-associated renal cell carcinoma In: Moch H, Humphrey PA, Ulbright TM., et al. eds. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: International Agency for Research on Cancer; 2016:39.

Thway K, du Parcq J, Larkin JM, et al. Metastatic renal mucinous tubular and spindle cell carcinoma. Atypical behavior of a rare, morphologically bland tumor. Ann Diagn Pathol. 2012;16:407–410. PubMed

Dhillon J, Amin MB, Selbs E, et al. Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change. Am J Surg Pathol. 2009;33:44–49. PubMed

Bulimbasic S, Ljubanovic D, Sima R, et al. Aggressive high-grade mucinous tubular and spindle cell carcinoma. Hum Pathol. 2009;40:906–907. PubMed

Ren Q, Wang L, Al-Ahmadie HA, et al. Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features. Am J Surg Pathol. 2018;42:767–777. PubMed PMC

Peckova K, Martinek P, Sperga M, et al. Mucinous spindle and tubular renal cell carcinoma: analysis of chromosomal aberration pattern of low-grade, high-grade, and overlapping morphologic variant with papillary renal cell carcinoma. Ann Diagn Pathol. 2015;19:226–231. PubMed

Sadimin ET, Chen YB, Wang L, et al. Chromosomal abnormalities of high-grade mucinous tubular and spindle cell carcinoma of the kidney. Histopathology. 2017;71:719–724. PubMed

Cossu-Rocca P, Eble JN, Delahunt B, et al. Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. Mod Pathol. 2006;19:488–493. PubMed

Ged Y, Chen YB, Knezevic A, et al. Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. Clin Genitourin Cancer. 2019;17:268–274 e261. PubMed PMC

Mehra R, Vats P, Cieslik M, et al. Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. Cancer Discov. 2016;6:1258–1266. PubMed PMC

Wang L, Zhang Y, Chen YB, et al. VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. Am J Surg Pathol. 2018;42:1571–1584. PubMed PMC

Yang XJ, Zhou M, Hes O, et al. Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization. Am J Surg Pathol. 2008;32:177–187. PubMed

Sarungbam J, Mehra R, Tomlins SA, et al. Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile. Mod Pathol. 2019;32:701–709. PubMed PMC

Osunkoya AO, Young AN, Wang W, et al. Comparison of gene expression profiles in tubulocystic carcinoma and collecting duct carcinoma of the kidney. Am J Surg Pathol. 2009;33:1103–1106. PubMed

Al-Hussain TO, Cheng L, Zhang S, et al. Tubulocystic carcinoma of the kidney with poorly differentiated foci: a series of 3 cases with fluorescence in situ hybridization analysis. Hum Pathol. 2013;44:1406–1411. PubMed

Smith SC, Trpkov K, Chen YB, et al. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma. Am J Surg Pathol. 2016;40:1457–1472. PubMed PMC

Kuroda N, Shiotsu T, Hes O, et al. Acquired cystic disease-associated renal cell carcinoma with gain of chromosomes 3, 7, and 16, gain of chromosome X, and loss of chromosome Y. Med Mol Morphol. 2010;43:231–234. PubMed

Kuroda N, Tamura M, Hamaguchi N, et al. Acquired cystic disease-associated renal cell carcinoma with sarcomatoid change and rhabdoid features. Ann Diagn Pathol. 2011;15:462–466. PubMed

Kuroda N, Yamashita M, Kakehi Y, et al. Acquired cystic disease-associated renal cell carcinoma: an immunohistochemical and fluorescence in situ hybridization study. Med Mol Morphol. 2011;44:228–232. PubMed

Cossu-Rocca P, Eble JN, Zhang S, et al. Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study. Mod Pathol. 2006;19:780–787. PubMed

Kuntz E, Yusenko MV, Nagy A, et al. Oligoarray comparative genomic hybridization of renal cell tumors that developed in patients with acquired cystic renal disease. Hum Pathol. 2010;41:1345–1349. PubMed

Moch H, Amin M, Argani P, et al. Renal cell tumors In: Moch H, Humphrey P, Ulbright T, et al. eds. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer; 2016:14–17.

Guo J, McKenney JK. The Pathology of von Hippel-Lindau Disease. Pathol Case Rev. 2014;19:49–56.

Cheng L, Williamson SR, Zhang S, et al. Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy. Expert Rev Anticancer Ther. 2010;10:843–864. PubMed

Shuch B, Vourganti S, Ricketts CJ, et al. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol. 2014;32:431–437. PubMed PMC

Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology. 2012;44:285–292. PubMed

Gill AJ. Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology. 2018;72:106–116. PubMed

Gill AJ, Benn DE, Chou A, et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol. 2010;41:805–814. PubMed

van Nederveen FH, Gaal J, Favier J, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009;10:764–771. PubMed PMC

Burnichon N, Briere JJ, Libe R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19:3011–3020. PubMed PMC

Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011;96:E1472–1476. PubMed

Benn DE, Zhu Y, Andrews KA, et al. Bayesian approach to determining penetrance of pathogenic SDH variants. J Med Genet. 2018;55:729–734. PubMed PMC

Gill AJ, Amin MB, Smith S, et al. Succinate dehydrogenase-deficient renal carcinoma In: Moch H, Humphrey PA, Ulbright TM., et al. eds. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: International Agency for Research on Cancer; 2016:35–36.

Gill AJ, Pachter NS, Clarkson A, et al. Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. N Engl J Med. 2011;364:885–886. PubMed

Gill AJ, Pachter NS, Chou A, et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol. 2011;35:1578–1585. PubMed

Paik JY, Toon CW, Benn DE, et al. Renal carcinoma associated with succinate dehydrogenase B mutation: a new and unique subtype of renal carcinoma. J Clin Oncol. 2014;32:e10–13. PubMed

Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. 2014;38:1588–1602. PubMed PMC

Williamson SR, Eble JN, Amin MB, et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol. 2015;28:80–94. PubMed

Gill AJ, Lipton L, Taylor J, et al. Germline SDHC mutation presenting as recurrent SDH deficient GIST and renal carcinoma. Pathology. 2013;45:689–691. PubMed

Ozluk Y, Taheri D, Matoso A, et al. Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma. Hum Pathol. 2015;46:1951–1955. PubMed

Yakirevich E, Ali SM, Mega A, et al. A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic Profiling. Am J Surg Pathol. 2015;39:858–863. PubMed

Harrison WJ, Andrici J, Maclean F, et al. Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings. Am J Surg Pathol. 2016;40:599–607. PubMed PMC

Turchini J, Cheung VKY, Tischler AS, et al. Pathology and genetics of phaeochromocytoma and paraganglioma. Histopathology. 2018;72:97–105. PubMed

Trpkov K, Hes O, Agaimy A, et al. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome. Am J Surg Pathol. 2016;40:865–875. PubMed

Pivovarcikova K, Martinek P, Grossmann P, et al. Fumarate hydratase deficient renal cell carcinoma: Chromosomal numerical aberration analysis of 12 cases. Ann Diagn Pathol. 2019;39:63–68. PubMed

Lau HD, Chan E, Fan AC, et al. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-Deficient Renal Cell Carcinoma in 32 Patients. Am J Surg Pathol. 2019. PubMed

Shyu I, Mirsadraei L, Wang X, et al. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples. Cancer Cytopathol. 2018;126:992–1002. PubMed PMC

Chen YB, Brannon AR, Toubaji A, et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol. 2014;38:627–637. PubMed PMC

Muller M, Guillaud-Bataille M, Salleron J, et al. Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration. Mod Pathol. 2018;31:974–983. PubMed

Miettinen M, Felisiak-Golabek A, Wasag B, et al. Fumarase-deficient Uterine Leiomyomas: An Immunohistochemical, Molecular Genetic, and Clinicopathologic Study of 86 Cases. Am J Surg Pathol. 2016;40:1661–1669. PubMed PMC

Merino MJ, Linehan WM. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated renal cell carcinoma In: Moch H, Humphrey PA, Ulbright TM., et al. eds. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: International Agency for Research on Cancer; 2016:25–26.

Shyu I, Mirsadraei L, Wang X, et al. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples. Cancer Cytopathol. 2018. PubMed PMC

Adeniran AJ, Shuch B, Humphrey PA. Hereditary Renal Cell Carcinoma Syndromes: Clinical, Pathologic, and Genetic Features. Am J Surg Pathol. 2015;39:e1–e18. PubMed

Guo J, Tretiakova MS, Troxell ML, et al. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am J Surg Pathol. 2014;38:1457–1467. PubMed

Yang P, Cornejo KM, Sadow PM, et al. Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol. 2014;38:895–909. PubMed PMC

Chen YB, Mirsadraei L, Jayakumaran G, et al. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm. Am J Surg Pathol. 2019;43:121–131. PubMed PMC

Mehra R, Vats P, Cao X, et al. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. Eur Urol. 2018;74:483–486. PubMed PMC

Palsgrove DN, Li Y, Pratilas CA, et al. Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum. Am J Surg Pathol. 2018;42:1166–1181. PubMed PMC

Parilla M, Kadri S, Patil SA, et al. Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations? Am J Surg Pathol. 2018;42:911–917. PubMed

Trpkov K, Abou-Ouf H, Hes O, et al. Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): Further Morphologic and Molecular Characterization of ESC RCC as a Distinct Entity. Am J Surg Pathol. 2017. PubMed

Trpkov K, Hes O, Bonert M, et al. Eosinophilic, Solid, and Cystic Renal Cell Carcinoma: Clinicopathologic Study of 16 Unique, Sporadic Neoplasms Occurring in Women. Am J Surg Pathol. 2016;40:60–71. PubMed

Tretiakova MS. Eosinophilic solid and cystic renal cell carcinoma mimicking epithelioid angiomyolipoma: series of 4 primary tumors and 2 metastases. Hum Pathol. 2018;80:65–75. PubMed

Li Y, Reuter VE, Matoso A, et al. Re-evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients. Histopathology. 2018;72:588–600. PubMed PMC

Williamson SR. Renal cell carcinomas with a mesenchymal stromal component: what do we know so far? Pathology. 2019;51:453–462. PubMed

Parilla M, Alikhan M, Al-Kawaaz M, et al. Genetic Underpinnings of Renal Cell Carcinoma With Leiomyomatous Stroma. Am J Surg Pathol. 2019;43:1135–1144. PubMed

Jia L, Jayakumaran G, Al-Ahmadie H, et al. Expanding the Morphologic Spectrum of Sporadic Renal Cell Carcinoma (RCC) Harboring Somatic TSC or MTOR Alterations: Analysis of 8 Cases with Clear Cytoplasm and Leiomyomatous Stroma. Mod Pathol. 2019;32:78–79 (abstract).

Williamson SR, Hornick JL, Eble JN, et al. Renal cell carcinoma with angioleiomyoma-like stroma and clear cell papillary renal cell carcinoma: exploring SDHB protein immunohistochemistry and the relationship to tuberous sclerosis complex. Hum Pathol. 2018;75:10–15. PubMed

Verkarre V, Mensah A, Leroy X, et al. A Clinico-Pathologic Study of 17 Patients With Renal Cell Carcinoma Associated With Leiomyomatous Stroma Identifies a Strong Association With Tuberous Sclerosis. Lab Invest. 2015;95:266A–266A.

He H, Trpkov K, Martinek P, et al. “High-grade oncocytic renal tumor”: morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Arch. 2018;473:725–738. PubMed

Trpkov K, Bonert M, Gao Y, et al. High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex. Histopathology. 2019;75:440–442. PubMed

Hakimi AA, Tickoo SK, Jacobsen A, et al. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Mod Pathol. 2015;28:845–853. PubMed PMC

Sato Y, Yoshizato T, Shiraishi Y, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013. PubMed

Hirsch MS, Barletta JA, Gorman M, et al. Renal Cell Carcinoma With Monosomy 8 and CAIX Expression: A Distinct Entity or Another Member or the Clear Cell Tubulopapillary RCC/RAT Family? Mod Pathol. 2015;28:229A (abstract).

Shah RB, Stohr BA, Tu ZJ, et al. “Renal Cell Carcinoma With Leiomyomatous Stroma” Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. Am J Surg Pathol. 2019. PubMed

DiNatale RG, Gorelick AN, Makarov V, et al. Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. Eur Urol Focus. 2019. PubMed PMC

Argani P, Reuter VE, Zhang L, et al. TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity. Am J Surg Pathol. 2016;40:1484–1495. PubMed PMC

Andeen NK, Qu X, Antic T, et al. Clinical Utility of Chromosome Genomic Array Testing for Unclassified and Advanced-Stage Renal Cell Carcinomas. Arch Pathol Lab Med. 2019;143:494–504. PubMed

Debelenko LV, Raimondi SC, Daw N, et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol. 2011;24:430–442. PubMed

Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer. 2012;118:4427–4436. PubMed

Sukov WR, Hodge JC, Lohse CM, et al. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol. 2012;25:1516–1525. PubMed

Bodokh Y, Ambrosetti D, Kubiniek V, et al. ALK-TPM3 rearrangement in adult renal cell carcinoma: Report of a new case showing loss of chromosome 3 and literature review. Cancer Genet. 2018;221:31–37. PubMed

Cajaiba MM, Jennings LJ, George D, et al. Expanding the spectrum of ALK-rearranged renal cell carcinomas in children: Identification of a novel HOOK1-ALK fusion transcript. Genes Chromosomes Cancer. 2016;55:814–817. PubMed PMC

Cajaiba MM, Jennings LJ, Rohan SM, et al. ALK-rearranged renal cell carcinomas in children. Genes Chromosomes Cancer. 2016;55:442–451. PubMed

Hodge JC, Pearce KE, Sukov WR. Distinct ALK-rearranged and VCL-negative papillary renal cell carcinoma variant in two adults without sickle cell trait. Mod Pathol. 2013;26:604–605. PubMed

Jeanneau M, Gregoire V, Desplechain C, et al. ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. Pathol Res Pract. 2016;212:1064–1066. PubMed

Kuroda N, Liu Y, Tretiakova M, et al. Clinicopathological Study of Seven Cases of ALK-positive Renal Tumor Identification of New Fusion Partners including CLIP1 and KIF5B Genes. Mod Pathol. 2019;32:85.

Kuroda N, Sugawara E, Kusano H, et al. A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects. Pol J Pathol. 2018;69:109–113. PubMed

Kusano H, Togashi Y, Akiba J, et al. Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene. Am J Surg Pathol. 2016;40:761–769. PubMed

Lee C, Park JW, Suh JH, et al. ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. Korean J Pathol. 2013;47:452–457. PubMed PMC

Marino-Enriquez A, Ou WB, Weldon CB, et al. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer. 2011;50:146–153. PubMed

Pal SK, Bergerot P, Dizman N, et al. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. Eur Urol. 2018;74:124–128. PubMed

Smith NE, Deyrup AT, Marino-Enriquez A, et al. VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy? Am J Surg Pathol. 2014;38:858–863. PubMed PMC

Thorner PS, Shago M, Marrano P, et al. TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: Report of a case with a TPM3-ALK translocation. Pathol Res Pract. 2016;212:937–942. PubMed

Yu W, Wang Y, Jiang Y, et al. Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review. Histopathology. 2017;71:53–62. PubMed

Hang JF, Chung HJ, Pan CC. ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology. Virchows Arch. 2020. PubMed

Taneja K, Cheng L, Al-Obaidy K, et al. Clear Cell Renal Cell Carcinoma With a Poorly-Differentiated Component: A Novel Variant Causing Potential Diagnostic Difficulty. Mod Pathol. 2019;32:147–148 (abstract). PubMed

Kouba EJ, Eble JN, Simper N, et al. High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment. Mod Pathol. 2016;29:1347–1357. PubMed

Wang L, Williamson SR, Wang M, et al. Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy. Mol Cancer. 2014;13:39. PubMed PMC

D’Avella C, Abbosh P, Pal SK, et al. Mutations in renal cell carcinoma. Urol Oncol. 2018. PubMed

Kwiatkowski DJ, Choueiri TK, Fay AP, et al. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016;22:2445–2452. PubMed PMC

Kammerer-Jacquet SF, Deleuze A, Saout J, et al. Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. Int J Mol Sci. 2019;20. PubMed PMC

Grimm MO, Leucht K, Grunwald V, et al. New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. J Clin Med. 2020;9. PubMed PMC

Nunes-Xavier CE, Angulo JC, Pulido R, et al. A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma. Curr Urol Rep. 2019;20:1. PubMed

Flaifel A, Xie W, Braun DA, et al. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clin Cancer Res. 2019;25:6080–6088. PubMed PMC

McKay RR, Bosse D, Xie W, et al. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. Cancer Immunol Res. 2018;6:758–765. PubMed PMC

Do we need an updated classification of oncocytic renal tumors? : Emergence of low-grade oncocytic tumor (LOT) and eosinophilic vacuolated tumor (EVT) as novel renal entities

Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients

New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia

Molekularpathologie bei urologischen Tumoren : Empfehlungen der Konsenskonferenz der Internationalen Gesellschaft für Uropathologie (ISUP) 2019